home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences

Search

 
  Good Governance: Risk Management in a High Risk Industry  
  July 05, 2002

Biotechnology

 
     
  Biotechnology Investment Today, New York
24 July 2002


12.00 1.00 Registration & Lunch

1.00 1.20 Wall Street Briefing
Why is good governance in biotech important to the markets?

1.20 - 1.40 Business Briefing
Introduction to Corporate Risk Management

1.40 2.50 Panel: Long Range Planning Against Financial Risk

Balancing short term survival against long term goals stable corporate financing throughout the business cycle

Managing communication and investor relations planning for disclosure and due diligence

Strategic insurance planning for biotech companies

2.50 3.10 Breakout

3.10 4.20 Panel: Preparing for Legal, Regulatory and Technical Risks

Corporate strategy for effective IP management, technology transfer and licensing in biotech companies

Avoiding risk and maximising return in partnerships how to undertake and survive due diligence

Building successful R & D partnerships

Clinical Trial Liability Risk Management

420 4.40 Breakout

4.40 5.50 Panel: Building Strong Corporate Defences Against Risk

Corporate structuring acting early to protect shareholder value

Creating a management structure for long-term growth and stability

Corporate and personal liability risks and how to insure against them

5.50 - 6.00 Wrap-up
Paul Wake, Editor-in-Chief, Biotechnology Investment Today

6.00 8.30 Investor Network Reception
 
 
Organized by: Biotechnology Investment Today
Invited Speakers: Dan D'Agostino, Managing Director, Punk Ziegal & Company

Julian Fisher, Director & Managing Consultant, Reuters Business Consulting

Ellen Corenswet, Partner, Brobeck, Phleger & Harrison LLP

Anthony Santoro, VP, American International Group

Nigel Howard, Partner, Brobeck, Phleger & Harrison LLC

Theodore Roumel, Deputy Director of Technology Transfer, National Institutes of Health

Robert Cook, CFO, Pharmos Corporation

Gene Mancino, President, Blau Mancino Associates

Lisa Boutera, VP, American International Group
 
Deadline for Abstracts: 19 July 2002
 
Registration: Registration is open to CEOs and Directors of biotech and pharmaceutical companies
E-mail: rowan@investinbiotech.com
 
  Posted by:   Paul Wake, Editor in Chief, Biotechnology Investment Today  
Host: host213-123-223-73.in-addr.btopenworld.com
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 1995-2002 HUM-MOLGEN. All rights reserved. Liability and Copyright.